Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy and Postpartum
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 129
- 试验地点
- 9
- 主要终点
- Number of PCR confirmed cases among pregnant women
研究概览
简要总结
It still unclear how SARS-CoV-2 affects pregnant women and their offspring, as well as which factors may influence obstetrical disease and outcomes, including the timing of maternal viral exposure by gestational age, the effects of parity, age, host immune responses, coexisting medical and obstetrical conditions and the effects of treatment regimens. While further information is gathered, based on the existing evidence from other infections causing pneumonia, pregnant women should be considered to be at high risk for developing severe infection during the current COVID-19 epidemic. Results from clinical trials with HCQ in nonpregnant adults may not be directly extrapolated to pregnant women given the special features of the pregnancy status. Thus, clinical research is urgently needed to improve the care and reduce the risk of poor pregnancy outcomes of women in this and in future epidemics.
详细描述
This is a randomized, double blinded, placebo-controlled multicenter clinical trial including 714 pregnant women (200 SARS-CoV-2 infected -100 symptomatic with mild disease and 100 asymptomatic- pregnant women and 514 SARS-CoV-2 uninfected pregnant women who are contacts with a SARS-CoV-2 case) with the main objectives of assessing the safety and efficacy of oral hydroxychloroquine (HCQ) in reducing maternal viral shedding by PCR, and preventing incident SARS-CoV-2 infection and disease severity. Pregnant women undergoing antenatal follow up at five maternity hospitals, presenting at least one sign and/or one mild suggestive symptoms and a positive SARS-CoV-2 PCR test, or who are contacts of a suspected or confirmed case, will be recruited and randomized 1:1 to receive HCQ orally (400 mg/day for 3 days, followed by 200 mg/day for 11 days) or placebo. Women will be followed up for the duration of the intervention. One week after intervention completion, a SARS-CoV-2 PCR test will be repeated. At delivery, the pregnancy outcome will be registered, and a cord blood sample will be collected to measure for IgG and IgM of SARS-CoV-2. A neonatal nasopharyngeal aspirate will be collected to perform PCR SARS-CoV-2 testing.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Presenting with fever (≥37.5ºC) and/or one mild symptom suggestive of COVID-19 disease (cough, dyspnoea, chills, odynophagia, diarrhoea, muscle pain, anosmia, taste disorder, headache) OR contact of a SARS-CoV-2 confirmed or suspected case in the past 14 days
- •More than 12 weeks of gestation (dated by ultrasonography)
- •Agreement to deliver in the study hospitals
排除标准
- •Known hypersensitivity to HCQ or other 4-aminoquinoline compounds
- •History of retinopathy of any aetiology
- •Concomitant use of digoxin, cyclosporine, cimetidine
- •Known liver disease
- •Clinical history of cardiac pathology including known long QT syndrome
- •Unable to cooperate with the requirements of the study
- •Participating in other intervention studies
- •Delivery onset (characterized by painful uterine contractions and variable changes of the cervix, including some degree of effacement and slower progression of dilatation up to 5 cm for first and subsequent labours)
研究组 & 干预措施
Hydroxychloroquine
Participants will be then randomized in a 1:1 ratio to HCQ (400 mg/day for three days, followed by 200 mg/day for 11 days)
干预措施: Hydroxychloroquine (Drug)
Placebo
Participants will be then randomized in a 1:1 ratio to placebo (2 tablets for three days, followed by one tablet for 11 days).
干预措施: Placebo (Drug)
结局指标
主要结局
Number of PCR confirmed cases among pregnant women
时间窗: 21 days after intervention
Number of PCR-confirmed infected pregnant women assessed from collected nasopharyngeal and oropharyngeal swabs at day 21 after treatment start
次要结局
- Proportion of neonates with SARS-CoV-2- intrauterine infection by PCR-confirmed SARS-CoV-2-infection in nasopharyngeal aspirate.(through study completion, an average of 1 year)
- Proportion of neonates with clinical signs/symptoms of COVID-19(through study completion, an average of 1 year)
- Incidence of preeclampsia(through study completion, an average of 1 year)
- Prevalence of intrauterine growth restriction(through study completion, an average of 1 year)
- Prevalence of low birth weight (<10th centile according to local standards)(through study completion, an average of 1 year)
- Prevalence of preterm birth (<37 weeks of gestational age)(through study completion, an average of 1 year)
- Incidence of COVID-19-related admissions(through study completion, an average of 1 year)
- Incidence of COVID-19 disease during pregnancy(through study completion, an average of 1 year)
- Incidence of all-cause admissions(through study completion, an average of 1 year)
- Incidence of all-cause outpatient attendances(through study completion, an average of 1 year)
- Mean duration of symptoms-signs of COVID-19(through study completion, an average of 1 year)
- Frequency and severity of adverse events(through study completion, an average of 1 year)
- Incidence of SARS-CoV-2 infections during pregnancy(through study completion, an average of 1 year)
- Neonatal morbidity(through study completion, an average of 1 year)
- Neonatal mortality rate(through study completion, an average of 1 year)
- Incidence of gestational diabetes(through study completion, an average of 1 year)
- Frequency of congenital malformations(through study completion, an average of 1 year)
- Maternal mortality rate(through study completion, an average of 1 year)
- Prevalence of embryo and foetal losses (miscarriages and stillbirths)(through study completion, an average of 1 year)
- Proportion of adverse perinatal outcome(through study completion, an average of 1 year)